45 / 88
45
Tuesday, 20 June 2017
/ Scientific Programme
WFSBP 2017
TUE
019
Structural and functional correlates of serum Solu-
ble IL-6 receptor level in patients with Bipolar Disorder
(BP)
Ya-Mei Bai, Taiwan
P.-C. Tu, C.-T. Li, T.-P. Su
020
Does N-acetylcysteine decrease oxidative stress
biomarkers in urine among patients suffering from
Bipolar Disorder (BP)?
Pernille Kempel Ellegaard, Denmark
R. W. Licht, H. E. Poulsen, C. T. Nielsen
P-10
POSTER TOUR
13:00–14:30
Congress Hall A 1
Schizophrenia 1
Chair:
Oliver Howes, United Kingdom
001
Schizotypy in ultra-high risk for psychosis:
Its relations with basic symptoms
Suk-Kyoon An, Republic of Korea
M.-J. Bang
002
Low level of paraoxonase 1 activity and increased
proinflammatory and anti-inflammatory cytokines are
associated in drug naïve first episode psychosis
Chiara Bortolasci, Australia
K. Landucci, F. Brinholi, C. de Farias, L. Higachi,
E. Moreira, C. Noto, M. Maes, D. Barbosa
003
Amisulpride switching in schizophrenic patients
who showed suboptimal effect and / or tolerability to
current antipsychotics in a naturalistic setting:
An explorative study
Jung-Jin Kim, Republic of Korea
J.-E. Jeong, Y.-M. Kim, S.-M. Wang, K.-P. Kwak, H.-K. Yoon,
C.-U. Pae, W.-M. Bahk
004
Clinical assessment interview for negative symp-
toms: Validation of the Czech version
Ladislav Hosák, Czech Republic
K. Hosakova, L. Viktorova, M. Lecbych
005
Gesture performance as a possible trait marker in
schizophrenia: Test-retest reliability of gesture perfor-
mance in schizophrenia patients, unaffected relatives
and healthy controls
Sarah Eisenhardt, Switzerland
K. Stegmayer, J. Moor, T. Vanbellingen, S. Bohlhalter,
S. Walther
006
Relationship between symptom severity and vita-
min D deficiency in first-episode psychosis
Ricardo Coentre, Portugal
C. Gois, M. L. Figueira, M. Talina
007
Differences in social functioning among patients
with major psychiatric disorders: Interpersonal commu-
nication is impaired in patients with schizophrenia and
correlates with an increase in schizotypal traits
Takamitsu Shimada, Japan
K. Ohi, T. Yasuyama, T. Uehara, Y. Kawasaki
008
First episode of schizophrenia is followed by
changes in activity of blood amine oxidases
Marat Uzbekov, Russia
V. Brilliantova, S. Shikhov, E. Skokina
009
Validation of the Comprehensive ICF Core Set for
schizophrenia from the perspective of psychiatrists
Laura Nuño Gómez, Spain
M. Barrios, E. Rojo, J. Gómez Benito, G. Guilera
011
Effect of brexpiprazole on long-term remission in
adults with schizophrenia: Results from a randomized,
double-blind, placebo-controlled, maintenance study
Emmanuelle Weiller, Denmark
M. Hobart, S. Pfister, A. Forbes, J. Ouyang, C. Weiss
013
Clozapine use rate influenced by seasonal birth
and onset age: Big data analysis of Korean patients with
schizophrenia
Seung-Hwan Lee, Republic of Korea
J.-S. Kim, S.-W. Hahn, W.-Y. Jung, Y.-M. Jae
014
Relevant areas of functioning in schizophrenia:
From what perspective?
Oscar Pino López, Spain
M. Barrios, G. Guilera, E. Rojo, J. Gómez
015
Short-term and long-term efficacy of brexpipra-
zole in adults with schizophrenia: Effect across Marder
factors
Catherine Weiss, USA
A. Forbes, M. Hobart, S. Pfister, J. Ouyang, E. Weiller
016
Polypharmacy and psychotropic drug loading in
patients with schizophrenia in Asian countries: The
REAP-AP4 study
Shih-Ku Lin, Taiwan
017
Factors affecting quality of life and family burden
among the families of patients with schizophrenia
Chul-Eung Kim, Republic of Korea
019
Negative symptoms of schizophrenia: there will be
a potential role for antidepressants? – a case report
Raquel Serrano, Portugal
H. Medeiros, J. Ramos, T. Maia